{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:53:05Z","timestamp":1761238385459,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,3,27]],"date-time":"2017-03-27T00:00:00Z","timestamp":1490572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2017,3,27]],"date-time":"2017-03-27T00:00:00Z","timestamp":1490572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST104-2320-B-038-028"],"award-info":[{"award-number":["MOST104-2320-B-038-028"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s10637-017-0457-9","type":"journal-article","created":{"date-parts":[[2017,3,27]],"date-time":"2017-03-27T08:54:10Z","timestamp":1490604850000},"page":"427-435","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells"],"prefix":"10.1007","volume":"35","author":[{"given":"Yi-Yen","family":"Yeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Ping","family":"Liou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueh-Lun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Yi-Chung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huei-Mei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,27]]},"reference":[{"key":"457_CR1","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1126\/science.2406902","volume":"247","author":"GQ Daley","year":"1990","unstructured":"Daley GQ, Van Etten RA, Baltimore D (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome. Science 247:824\u2013830","journal-title":"Science"},{"key":"457_CR2","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/nrc2147","volume":"7","author":"JV Melo","year":"2007","unstructured":"Melo JV, Barnes DJ (2007) Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 7:441\u2013453","journal-title":"Nat Rev Cancer"},{"key":"457_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/sj.leu.2403241","volume":"18","author":"LS Steelman","year":"2004","unstructured":"Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA (2004) JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18:189\u2013218","journal-title":"Leukemia"},{"key":"457_CR4","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"TP Hughes","year":"2003","unstructured":"Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP, International Randomised Study of Interferon versus STI571 (IRIS) Study Group (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349:1423\u20131432","journal-title":"N Engl J Med"},{"key":"457_CR5","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876\u2013880","journal-title":"Science"},{"key":"457_CR6","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","volume":"110","author":"J Cortes","year":"2007","unstructured":"Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O\u2019Brien S, Garcia-Manero G, Giles F, Breeden M, Reeves N, Wierda WG, Jones D (2007) Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 110:4005\u20134011","journal-title":"Blood"},{"key":"457_CR7","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O\u2019Hare","year":"2009","unstructured":"O\u2019Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA 3rd, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16:401\u2013412","journal-title":"Cancer Cell"},{"key":"457_CR8","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","volume":"367","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O\u2019Hare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M (2012) Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 367:2075\u20132088","journal-title":"N Engl J Med"},{"key":"457_CR9","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/nrd3253","volume":"9","author":"C Dumontet","year":"2010","unstructured":"Dumontet C, Jordan MA (2010) Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 9:790\u2013803","journal-title":"Nat Rev Drug Discov"},{"key":"457_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nrc2049","volume":"7","author":"JR Jackson","year":"2007","unstructured":"Jackson JR, Patrick DR, Dar MM, Huang PS (2007) Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 7:107\u2013117","journal-title":"Nat Rev Cancer"},{"key":"457_CR11","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1021\/jm070557q","volume":"50","author":"JP Liou","year":"2007","unstructured":"Liou JP, Wu CY, Hsieh HP, Chang CY, Chen CM, Kuo CC, Chang JY (2007) 4- and 5-aroylindoles as novel classes of potent antitubulin agents. J Med Chem 50:4548\u20134552","journal-title":"J Med Chem"},{"key":"457_CR12","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/ijc.2910180405","volume":"18","author":"E Klein","year":"1976","unstructured":"Klein E, Ben-Bassat H, Neumann H, Ralph P, Zeuthen J, Polliack A, Vanky F (1976) Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia. Int J Cancer 18:421\u2013431","journal-title":"Int J Cancer"},{"key":"457_CR13","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1007\/s10495-016-1264-z","volume":"21","author":"CW Chen","year":"2016","unstructured":"Chen CW, Lee YL, Liou JP, Liu YH, Liu CW, Chen TY, Huang HM (2016) A novel tubulin polymerization inhibitor, MPT0B206, downregulates Bcr-Abl expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cells. Apoptosis 21:1008\u20131018","journal-title":"Apoptosis"},{"key":"457_CR14","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S0092-8674(85)80053-2","volume":"41","author":"R Palacios","year":"1985","unstructured":"Palacios R, Steinmetz M (1985) Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell 41:727\u2013734","journal-title":"Cell"},{"key":"457_CR15","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1038\/sj.onc.1208421","volume":"24","author":"A Essafi","year":"2005","unstructured":"Essafi A, Fern\u00e1ndez de Mattos S, Hassen YA, Soeiro I, Mufti GJ, Thomas NS, Medema RH, Lam EW (2005) Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. Oncogene 24:2317\u20132329","journal-title":"Oncogene"},{"key":"457_CR16","doi-asserted-by":"publisher","first-page":"8601","DOI":"10.1074\/jbc.M707934200","volume":"283","author":"N Carayol","year":"2008","unstructured":"Carayol N, Katsoulidis E, Sassano A, Altman JK, Druker BJ, Platanias LC (2008) Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR\/p70 S6 kinase pathway. J Biol Chem 283:8601\u20138610","journal-title":"J Biol Chem"},{"key":"457_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","volume":"2","author":"NP Shah","year":"2002","unstructured":"Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117\u2013125","journal-title":"Cancer Cell"},{"key":"457_CR18","doi-asserted-by":"publisher","first-page":"17118","DOI":"10.1074\/jbc.272.27.17118","volume":"272","author":"P Giannakakou","year":"1997","unstructured":"Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JTM, Fojo T, Poruchynsky MS (1997) Paclitaxel-resistant human ovarian cancer cells have mutant \u03b2-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272:17118\u201317125","journal-title":"J Biol Chem"},{"key":"457_CR19","doi-asserted-by":"publisher","first-page":"C37","DOI":"10.1152\/ajpcell.00130.2013","volume":"306","author":"YW Huang","year":"2014","unstructured":"Huang YW, Lee WH, Tsai YH, Huang HM (2014) Activin a induction of erythroid differentiation sensitizes K562 chronic myeloid leukemia cells to a subtoxic concentration of imatinib. Am J Physiol Cell Physiol 306:C37\u2013C44","journal-title":"Am J Physiol Cell Physiol"},{"key":"457_CR20","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1023\/A:1025513106330","volume":"8","author":"F Mollinedo","year":"2003","unstructured":"Mollinedo F, Gajate C (2003) Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 8:413\u2013450","journal-title":"Apoptosis"},{"key":"457_CR21","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nrc1567","volume":"5","author":"R Ren","year":"2005","unstructured":"Ren R (2005) Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5:172\u2013183","journal-title":"Nat Rev Cancer"},{"key":"457_CR22","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","volume":"103","author":"B Calabretta","year":"2004","unstructured":"Calabretta B, Perrotti D (2004) The biology of CML blast crisis. Blood 103:4010\u20134022","journal-title":"Blood"},{"key":"457_CR23","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","volume":"113","author":"A Quintas-Cardama","year":"2009","unstructured":"Quintas-Cardama A, Cortes J (2009) Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113:1619\u20131630","journal-title":"Blood"},{"key":"457_CR24","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.leukres.2007.11.008","volume":"32","author":"Y Deguchi","year":"2008","unstructured":"Deguchi Y, Kimura S, Ashihara E, Niwa T, Hodohara K, Fujiyama Y, Maekawa T (2008) Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk Res 32:980\u2013983","journal-title":"Leuk Res"},{"key":"457_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10147-013-0641-7","volume":"19","author":"S Kimura","year":"2014","unstructured":"Kimura S, Ando T, Kojima K (2014) Ever-advancing chronic myeloid leukemia treatment. Int J Clin Oncol 19:3\u20139","journal-title":"Int J Clin Oncol"},{"key":"457_CR26","doi-asserted-by":"publisher","first-page":"32214","DOI":"10.1074\/jbc.M111525200","volume":"277","author":"AS Corbin","year":"2002","unstructured":"Corbin AS, Buchdunger E, Furet P, Druker BJ (2002) Analysis of the structural basis of specificity of the Abl kinase by STI571. J Biol Chem 277:32214\u201332219","journal-title":"J Biol Chem"},{"key":"457_CR27","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1158\/1535-7163.MCT-05-0101","volume":"4","author":"S Pricl","year":"2005","unstructured":"Pricl S, Fermeglia M, Ferrone M, Tamborini E (2005) T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study. Mol Cancer Ther 4:1167\u20131174","journal-title":"Mol Cancer Ther"},{"key":"457_CR28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11910-008-0010-5","volume":"8","author":"B Malik","year":"2008","unstructured":"Malik B, Stillman M (2008) Chemotherapy-induced peripheral neuropathy. Curr Neurol Neurosci Rep 8:56\u201365","journal-title":"Curr Neurol Neurosci Rep"},{"key":"457_CR29","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.2174\/1381612053764706","volume":"11","author":"NM Verrills","year":"2005","unstructured":"Verrills NM, Kavallaris M (2005) Improving the targeting of tubulin-binding agents: lessons from drug resistance studies. Curr Pharm Des 11:1719\u20131733","journal-title":"Curr Pharm Des"},{"key":"457_CR30","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1007\/s10637-013-0019-8","volume":"31","author":"TH Landowski","year":"2013","unstructured":"Landowski TH, Samulitis BK, Dorr RT (2013) The diaryl oxazole PC-046 is a tubulin-binding agent with experimental anti-tumor efficacy in hematologic cancers. Investig New Drugs 31:1616\u20131625","journal-title":"Investig New Drugs"},{"key":"457_CR31","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1007\/s10637-015-0232-8","volume":"33","author":"A Chan","year":"2015","unstructured":"Chan A, Singh AJ, Northcote PT, Miller JH (2015) Inhibition of human vascular endothelial cell migration and capillary-like tube formation by the microtubule-stabilizing agent peloruside A. Investig New Drugs 33:564\u2013574","journal-title":"Investig New Drugs"},{"key":"457_CR32","doi-asserted-by":"publisher","first-page":"10959","DOI":"10.1158\/0008-5472.CAN-06-1216","volume":"66","author":"R Chen","year":"2006","unstructured":"Chen R, Gandhi V, Plunkett W (2006) A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res 66:10959\u201310966","journal-title":"Cancer Res"},{"key":"457_CR33","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.3892\/ol.2015.3665","volume":"10","author":"W Zhou","year":"2015","unstructured":"Zhou W, Zhu W, Ma L, Xiao F, Qian W (2015) Proteasome inhibitor MG-132 enhances histone deacetylase inhibitor SAHA-induced cell death of chronic myeloid leukemia cells by an ROS-mediated mechanism and downregulation of the Bcr-Abl fusion protein. Oncol Lett 10:2899\u20132904","journal-title":"Oncol Lett"},{"key":"457_CR34","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3904\/kjim.2015.024","volume":"31","author":"DS Kim","year":"2016","unstructured":"Kim DS, Na YJ, Kang MH, Yoon SY, Choi CW (2016) Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells. Korean J Intern Med 31:357\u2013366","journal-title":"Korean J Intern Med"},{"key":"457_CR35","doi-asserted-by":"publisher","first-page":"e0148093","DOI":"10.1371\/journal.pone.0148093","volume":"11","author":"SM Wong","year":"2016","unstructured":"Wong SM, Liu FH, Lee YL, Huang HM (2016) MPT0B169, a new antitubulin agent, inhibits Bcr-Abl expression and induces mitochondrion-mediated apoptosis in nonresistant and imatinib-resistant chronic myeloid leukemia cells. PLoS One 11:e0148093","journal-title":"PLoS One"},{"key":"457_CR36","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/sj.onc.1200885","volume":"14","author":"R de Jong","year":"1997","unstructured":"de Jong R, Ten HJ, Heisterkamp N, Groffen J (1997) Tyrosine 207 in CRKL is the BCR\/ABL phosphorylation site. Oncogene 14:507\u2013513","journal-title":"Oncogene"},{"key":"457_CR37","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/cyto.a.10063","volume":"54","author":"JW Jacobberger","year":"2003","unstructured":"Jacobberger JW, Sramkoski RM, Frisa PS, Ye PP, Gottlieb MA, Hedley DW, Shankey TV, Smith BL, Paniagua M, Goolsby CL (2003) Immunoreactivity of Stat5 phosphorylated on tyrosine as a cell-based measure of Bcr\/Abl kinase activity. Cytometry A 54:75\u201388","journal-title":"Cytometry A"},{"key":"457_CR38","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.1038\/sj.onc.1209608","volume":"25","author":"S Fulda","year":"2006","unstructured":"Fulda S, Debatin KM (2006) Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25:4798\u20134811","journal-title":"Oncogene"},{"key":"457_CR39","doi-asserted-by":"publisher","first-page":"20049","DOI":"10.1074\/jbc.274.29.20049","volume":"274","author":"BB Wolf","year":"1999","unstructured":"Wolf BB, Green DR (1999) Suicidal tendencies: apoptotic cell death by caspase family proteinases. J Biol Chem 274:20049\u201320052","journal-title":"J Biol Chem"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-017-0457-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-017-0457-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-017-0457-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:06:59Z","timestamp":1678511219000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-017-0457-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,27]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["457"],"URL":"https:\/\/doi.org\/10.1007\/s10637-017-0457-9","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[2017,3,27]]},"assertion":[{"value":"15 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}